Real‐world non‐interventional long‐term post‐authorisation safety study of ruxolitinib in myelofibrosisFiorenza Barraco, Heinz Gisslinger, Richard Greil et al.|British Journal of Haematology|2020Cited by 30
Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 studyFranco Locatelli, Cristina Díaz de Heredia, Bülent Antmen et al.|The Lancet Haematology|2024Cited by 18
S245: RUXOLITINIB IN PEDIATRIC PATIENTS WITH TREATMENT-NAIVE OR STEROID-REFRACTORY CHRONIC GRAFT VERSUS HOST DISEASE: PRIMARY FINDINGS FROM THE PHASE II REACH5 STUDYFranco Locatelli, Cristina Díaz de Heredia, Bülent Antmen et al.|HemaSphere|2023Cited by 3
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC): Asia-Pacific (AP) trial subgroup analyses by baseline transaminase (ALT/AST)/α-fetoprotein (AFP) levelsShenghui Qin, Ann‐Lii Cheng, Chung‐Kan Tsao et al.|Journal of Clinical Oncology|2009Cited by 1
Impact of prior surgical resection with curative intent on the efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC): Subset analysis of the Asia-Pacific (AP) studyT.-S. Yang, Ann‐Lii Cheng, Shenghui Qin et al.|Journal of Clinical Oncology|2009Cited by 1